<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859781</url>
  </required_header>
  <id_info>
    <org_study_id>0810010067</org_study_id>
    <secondary_id>J591+Ketoconazole</secondary_id>
    <nct_id>NCT00859781</nct_id>
  </id_info>
  <brief_title>177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer</brief_title>
  <official_title>A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591
      in combination with ketoconazole and hydrocortisone against prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done because the standard treatments for prostate cancer that has
      returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal
      therapy are not curative. Existing treatments, such as the ketoconazole used as part of this
      study may decrease PSA temporarily, but unfortunately the cancer continues to grow. This
      experimental drug is designed to seek out all of the prostate cancer cells and to deliver a
      lethal dose of radiation to the areas of cancer, but not to normal areas. Some of the normal
      organs (liver, kidney and bone marrow) do receive some radiation dose that is within the
      acceptable limits.

      The experimental drug in this study includes an antibody (abbreviated: mAb) called &quot;J591&quot;. It
      is a protein molecule which can bind to a specific site on a prostate cancer cell. A very
      energetic radioactive (an unstable atom) metal called 177Lutetium (abbreviated: 177Lu) is
      attached to the J591 antibody. The fully assembled drug is called &quot;177Lu-J591&quot;. The study
      will assess the potential of the energy given off by the radioactive compound to kill cancer
      cell. This study may also involve the use of 111Indium (abbreviated 111In). This is also an
      energetic radioactive particle, but does not generally give off enough energy to kill cancer
      cells, but allows researchers to take pictures. This radioactive particle is also attached to
      the J591 antibody (called 111In-J591) and will serve as a placebo (treatment with no active
      medicine).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2009</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion free of radiographically evident metastases at 18 months by CT and/or MRI scan of the abdomen and pelvis, chest x-ray or CT scan of the chest and bone scan</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>every 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment</description>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <other_name>J591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)</description>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)</description>
    <arm_group_label>1. 177Lu-J591+Ketoconzole</arm_group_label>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <other_name>Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111In-J591</intervention_name>
    <description>111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment</description>
    <arm_group_label>2. 111In-J591 + ketoconazole</arm_group_label>
    <other_name>J591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate previously
             treated with surgery and/or radiotherapy.

          -  Biochemical progression (rising PSA) after medical or surgical castration

          -  High risk of systemic progression defined as:

               1. Rising PSA as defined above and either:

               2. Absolute PSA &gt; 20 ng/mL AND/OR

               3. PSA doubling time &lt; 8 months

          -  No evidence of local recurrence or distant metastases

          -  Age &gt;18 years.

          -  Serum testosterone &lt; 50 ng/ml

          -  Patients capable of fathering children must agree to use an effective method of
             contraception for the duration of the trial.

          -  Subjects on bisphosphonate therapy must be on a stable dose and must have started
             therapy &gt; 4 weeks prior to protocol therapy.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Use of red blood cell or platelet transfusions within 4 weeks of treatment

          -  Use of hematopoietic growth factors within 4 weeks of treatment

          -  Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment

          -  Prior radiation therapy encompassing &gt;25% of skeleton

          -  Prior treatment with 89-Strontium or 153-Samarium containing compounds (e.g.
             Metastron®, Quadramet®)

          -  Platelet count &lt;150,000/mm3

          -  Absolute neutrophil count (ANC) &lt;2,000/mm3

          -  Hematocrit &lt;30 percent or Hemoglobin &lt; 10 g/dL

          -  Abnormal coagulation profile (PT or INR, PTT) &gt; 1.3x ULN

          -  Serum creatinine &gt;2.5 mg/dL

          -  AST (SGOT) &gt;2x ULN

          -  Bilirubin (total) &gt;1.5x ULN

          -  Serum calcium &gt;11 mg/dL

          -  Active serious infection

          -  Active angina pectoris or NY Heart Association Class III-IV

          -  Karnofsky Performance Status &lt;70

          -  Life expectancy &lt;12 months

          -  History of deep vein thrombosis and/or pulmonary embolus within 3 months of study
             entry

          -  Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or
             hematological organ systems which might preclude completion of this study or interfere
             with determination of causality of any adverse effects experienced in this study.

          -  Prior investigational therapy (medications or devices) within 6 weeks of treatment.

          -  Prior use of ketoconazole for the purposes of prostate cancer therapy

          -  Known history of HIV.

          -  Currently active other malignancy other than non-melanoma skin cancer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott T Tagawa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GUONC Research Team</last_name>
    <email>guonc@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive cancer center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Quinn, MD, PhD</last_name>
      <phone>323-865-3956</phone>
      <email>diquinn@usc.edu</email>
    </contact>
    <investigator>
      <last_name>David Quinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Alarcon</last_name>
      <phone>202-687-7607</phone>
      <email>sva24@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>George K Philips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Miles, RN</last_name>
      <phone>321-841-7607</phone>
      <email>Erin.Miles@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Julio Hajdenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhoda Loman</last_name>
      <email>rloman@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Constance Albany, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Zehr, RN, MA</last_name>
      <phone>319-353-8914</phone>
      <email>pamela-zehr@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Vaena, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Marx</last_name>
      <phone>631-675-5170</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUONC Research Team</last_name>
      <email>guonc@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Scott T Tagawa, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Tribble, RN</last_name>
    </contact>
    <investigator>
      <last_name>Leonard Appleman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

